LivaNova Initiates Process With CMS For Reconsideration Of National Medicare Coverage For VNS Therapy For Treatment-Resistant Depression

LivaNova PLC, a medical technology company, has initiated the process with the Centers for Medicare & Medicaid Services (CMS) to seek reconsideration of national Medicare coverage for VNS Therapy™ as treatment for consumers with unipolar treatment-resistant depression (TRD). The first step in the process for securing a National Coverage Determination (NCD) is the submission of a draft formal request for CMS reconsideration. 

VNS Therapy relies on an implanted device that sends mild electrical pulses to the vagus nerve, which then stimulates an area of the brain found to be associated with TRD. LivaNova’s VNS Therapy™ System is marketed . . .